From palliation to epigenetic therapy in myelofibrosis.

Abstract excerpt

Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. The molecular pathogenesis of this disease largely remains to be fully understood but the identification of the JAK2V617F mutation in more than half of patients was a major improvement in our understanding of the disease biology and may represent the first biologic marker useful for risk stratification, independently from...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angiogenesis Inhibitors
• Share to Boronic Acids
• Share to Bortezomib